English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  Positive outcomes for paediatric rhabdomyosarcoma ( RMS ) were high in Sweden during the 1990s, but the last decade has seen decreasing trends in overall survival rates. We investigated the incidence, patient and disease characteristics, treatment and outcome of  RMS  to see whether any reason could be found for this decline.    Methods  This study included 210 children under the age of 15 who were diagnosed with  RMS  and whose details were recorded in the population‐based Swedish Childhood Cancer Registry from 1984 to 2010.    Results  The overall annual incidence of  RMS  was 4.9 per million, and the 5‐year overall survival rates were 59 ± 7% in 1984–1989, 78 ± 5% in 1990–1999 and 71 ± 5% in 2000–2010. When patients with localised disease were analysed separately, there was no difference in the 5‐year survival rates between 1990 and 1999 (82 ± 5%) and 2000–2010 (81 ± 5%), but the outcome in 1984–1989 (53 ± 8%) was significantly worse. The prevalence of metastatic disease was unexpectedly high during 2000–2010 (28%, p = 0.010), compared to an overall mean of 18% for the whole study period.    Conclusion  Our results suggest that a higher rate of metastatic disease may explain the declining trend in overall survival rates in paediatric  RMS  in Sweden over the last decade.

Higher rates of metastatic disease may explain the declining trend in Swedish paediatric rhabdomyosarcoma survival rates